MRRSE announces addition of new report "Scleroderma Diagnostics and Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024" to its database

1. Scleroderma Diagnostics and Therapeutics Market Deep
Research Study with Forecast by 2024
Report Description
The scleroderma therapeutics and diagnostics market exhibits
high potential due to untapped needs and is set to grow
rapidly in the near future due to the increasing focus

2. globally on treatment of orphan diseases. The lack of
approved drugs in the market makes it a highly opportune
condition for players to convert their innovative drug ideas
into successful treatment methods for this rare chronic
inflammatory disease.
Request a Sample Copy of the Report @
http://www.mrrse.com/sample/2241
According to Transparency Market Research, the global
scleroderma diagnostics and therapeutics market was valued
at US$1,633.5 mn in 2015 and is projected to expand at a
CAGR of 9.7% from 2016 to 2024 to reach US$3,663.7 mn by
2024.

3. Physician and Patient Preference to make Immunosuppressive
Agents Leading Drug Category
Presently, there is no approved drug for treatment of this
orphan disease. Although drugs to manage symptomatic relief
are available in the scleroderma therapeutics market, the
treatment of scleroderma is challenging for a physician, since
no two patients are alike in the progress of their disease.
Thus, a host of different drugs are prescribed to every
patient, depending on the extent, severity and nature of their
symptoms.

4. It has been observed that patient consumption patterns in the
global scleroderma diagnostics and therapeutics market are
inclined towards immunosuppressive agents, which have
shown to provide relief against several symptoms in both
systemic and localized scleroderma cases. Moreover, of the
very few treatments identified to efficaciously modify the
course of scleroderma, physicians often recommend
immunosuppressive agents to manage the most common
symptoms of the disease. The segment, as a result, accounts
for the dominant share in the global market.
Inquiry on this report @ http://www.mrrse.com/enquiry/2241

5. Prostacyclin analogues have been found to have a potent
effect in treating systemic scleroderma patients who suffer
from pulmonary arterial hypertension. However, these drugs
are expensive and thus, even though a smaller sub-set of
patients is administered with these agents, their market value
is high. This segment grabbed over 8.0% share of the global
scleroderma therapeutics market in 2015, and is anticipated
to slightly decline by 2024 owing to availability of cheaper
alternatives within this segment.
Developed Regions to Continue to Command Dominance
Owing to better diagnostic and treatment rates, in part due
to proactive awareness-raising initiatives by various

6. foundations, have aided North America and Europe gain the
predominant share in the global scleroderma diagnostics and
therapeutics market. North America accounted for a share of
nearly 34.0% while Europe held nearly 30% of the global
scleroderma therapeutics market in 2015. This is attributed to
presence of renowned pharmaceutical companies, research
organizations, and institutes in the regions, which are
focused on finding a standard treatment for the condition.
The North America and Europe markets for scleroderma
diagnostics and therapeutics are expected to retain their
dominance in the global scleroderma diagnostics and
therapeutics market throughout the forecast period, exhibiting
CAGRs of 11.2% and 10.9%, respectively, over the period

7. between 2016 and 2024. The ongoing cutting-edge research
pertaining to scleroderma will aid the growth of a niche
scleroderma diagnostics and therapeutics market in these
regions.
Read Complete Report with TOC @
http://www.mrrse.com/scleroderma-diagnostics-therapeutics
Asia Pacific represents some of the world’s key emerging
economies, which have the potential to adopt quickly to new
therapies, provided they are available at reasonable costs.
Due to the price-sensitive nature of the market, as well as
availability of cheaper generics and reasonable clinical
diagnostic rates compared to North America and Europe, the

8. market for Asia Pacific gained the third position in terms of
market share in 2015. The Asia Pacific market will also
retain its position in the global market over the forecast
period, with factors such as large population and high unmet
needs working in favor of market expansion in the region.
About MRRSE
MRRSE stands for Market Research Reports Search Engine,
the largest online catalog of latest market research reports
based on industries, companies, and countries. MRRSE
sources thousands of industry reports, market statistics, and
company profiles from trusted entities and makes them
available at a click. Besides well-known private publishers,

9. the reports featured on MRRSE typically come from national
statistics agencies, investment agencies, leading media houses,
trade unions, governments, and embassies.
Contact US:
Corporate Office
State Tower
90 State Street, Suite 700
Albany, NY 12207
United States

10. Tel: +1-518-730-0559
Email: sales@mrrse.com